The relation of metabolic syndrome according to five definitions to cardiovascular risk factors - A population-based study

BMC Public Health

Volumn 9, Issue , 2009, Pages

  Lin, Cheng Chieh ^a,b,c,d   Liu, Chiu Shong ^a,b   Li, Chia Ing ^a   Lin, Wen Yuan ^a,b   Lai, Ming May ^a,b   Lin, Tsann ^a,b   Chang, Pei Chia ^a   Lee, Yih Dar ^e   Chen, Ching Chu ^a   Lin, Chih Hsueh ^a,b   Yang, Chuan Wei ^a   Hsiao, Chih Yi ^d   Chen, Walter ^d   Li, Tsai Chung ^d  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ANTHROPOMETRY; ARTICLE; CARDIOVASCULAR DISEASE; CLASSIFICATION; FEMALE; HUMAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NOMENCLATURE; RISK FACTOR; STATISTICAL MODEL; TAIWAN; WORLD HEALTH ORGANIZATION;

ADULT; ANTHROPOMETRY; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; TAIWAN; TERMINOLOGY AS TOPIC; WORLD HEALTH ORGANIZATION;

EID: 74949100198     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-9-484     Document Type: Article

References (52)

1. Cardiovascular morbidity and mortality associated with the metabolic syndrome. B Isomaa P Almgren T Tuomi,, et al. Diabetes Care 2001 24 683 689 10.2337/diacare.24.4.683 11315831
2. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam. BE Klein R Klein KE Lee, Diabetes Care 2002 25 1790 1794 10.2337/diacare.25.10.1790 12351479
3. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. HM Lakka DE Laaksonen TA Lakka LK Niskanen E Kumpusalo J Tuomilehto,, et al. JAMA 2002 288 2709 2716 10.1001/jama.288.21.2709 12460094
4. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. WHO, Geneva: World Health Organization 1999
5. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). B Balkau MA Charles, Diabet Med 1999 16 5 442 443 10.1046/j.1464-5491.1999.00059.x 10342346
6. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Adult Treatment Panel III, JAMA 2001 285 2486 2497 10.1001/jama.285.19.2486 11368702
7. The metabolic syndrome - a new worldwide definition. KG Alberti P Zimmet J Shaw, Lancet 2005 366 9491 1059 1062 10.1016/S0140-6736(05)67402-8 16182882 (Pubitemid 41338752)
8. Diagnosis and management of the metabolic syndrome: an American heart Association/National Heart, Lung, and Blood Institute Scientific Statement. SM Grundy JI Cleeman SR Daniels KA Donato RH Eckel BA Franklin DJ Gordon RM Krauss PJ Savage SC Smith Jr,, et al. Circulation 2005 112 17 2735 2752 10.1161/CIRCULATIONAHA.105.169404 16157765
9. What is the evidence that microalbuminuria is a predictor of cardiovascular disease events? MF Yuyun AI Adler NJ Wareham, Curr Opin Nephrol Hypertens 2005 14 271 6 10.1097/01.mnh.0000165895.90748.3b 15821422
10. [Relationship of metabolic syndrome and insulin resistance with microalbuminuria in senior citizens of rural communities in Japan - the Tanno and Sobetsu study - ]. T Tabeya H Ohnishi S Saitoh H Akasaka K Mitsumata M Chiba M Furugen M Mori K Shimamoto, Nippon Ronen Igakkai Zasshi - Japanese Journal of Geriatrics 2008 45 3 302 307 10.3143/geriatrics.45.302 18622115
11. Renal manifestations of metabolic syndrome in type 2 diabetes. K Hanai T Babazono Y Iwamoto, Diabetes Research & Clinical Practice 2008 79 2 318 324 10.1016/j.diabres.2007.08.032
12. Microalbuminuria and the metabolic syndrome and its components in the Chinese population. CC Lin CS Liu TC Li CC Chen CI Li WY Lin, European Journal of Clinical Investigation 2007 37 10 783 790 10.1111/j.1365-2362.2007.01865.x 17888089
13. The relationship of microalbuminuria with metabolic syndrome. HS Choi SH Ryu KB Lee, Nephron 2006 104 2 85 93 16785740
14. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. J Blacher R Asmar S Djane GM London ME Safar, Hypertension 1999 33 1111 1117 10334796
15. Metabolic syndrome, C-reactive protein and increased arterial stiffness in Japanese subjects. Y Saijo E Yoshioka T Fukui M Kawaharada R Kishi, Hypertension Research - Clinical & Experimental 2006 29 8 589 596 10.1291/hypres.29.589 (Pubitemid 44430467)
16. Impact of metabolic syndrome on brachial-ankle pulse wave velocity in Japanese. A Tsubakimoto I Saito T Mannami Y Naito S Nakamura Y Dohi K Yonemasu, Hypertension Research - Clinical & Experimental 2006 29 1 29 37 10.1291/hypres.29.29
17. Two new criteria of the metabolic syndrome: prevalence and the association with brachial-ankle pulse wave velocity in Japanese male workers. K Miyaki A Hara M Naito T Naito T Nakayama, Journal of Occupational Health 2006 48 2 134 140 10.1539/joh.48.134 16612043
18. Brachial-ankle pulse wave velocity and metabolic syndrome in a Japanese population: the Minoh study. N Nakanishi T Shiraishi M Wada, Hypertension Research - Clinical & Experimental 2005 28 2 125 131 10.1291/hypres.28.125 (Pubitemid 40663063)
19. Relationship between brachial-ankle pulse wave velocity and cardiovascular risk factors of the metabolic syndrome. KM Choi KW Lee JA Seo JH Oh SG Kim NH Kim DS Choi SH Baik, Diabetes Research & Clinical Practice 2004 66 1 57 61 10.1016/j.diabres.2004.02.014 (Pubitemid 39201372)
20. In addition to insulin resistance and obesity, brachial-ankle pulse wave velocity is strongly associated with metabolic syndrome in Chinese- A population-based study (Taichung Community Health Study, TCHS). WY Lin MM Lai CI Li CC Lin TC Li CC Chen T Lin CS Liu, Journal of Atherosclerosis and Thrombosis 2009 16 2 105 112 19403990
21. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. PM Ridker N Rifai L Rose JE Buring NR Cook, N Engl J Med 2002 347 1557 1565 10.1056/NEJMoa021993 12432042
22. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case control study. LH Kuller RP Tracy J Shaten EN Meilahn, Am J Epidemiol 1996 144 537 547 8797513
23. Association of testosterone, insulin-like growth factor-I, and C-reactive protein with metabolic syndrome in Chinese middle-aged men with a family history of type 2 diabetes. PC Tong CS Ho VT Yeung MC Ng WY So R Ozaki GT Ko RC Ma E Poon NN Chan, Journal of Clinical Endocrinology & Metabolism 2005 90 12 6418 6423 10.1210/jc.2005-0228 (Pubitemid 41759294)
24. A comparison of the prevalence of the MS and its complications using three proposed definitions in Korean subjects. KC Sung BJ Kim BS Kim WY Lee JB Park AM Wilson, American Journal of Cardiology 2009 103 12 1732 1735 10.1016/j.amjcard.2009.02.027 19539084
25. Metabolic Syndrome and Its Associated Risk Factors in a Taiwanese Metropolitan Adult Population. CC Lin CS Liu MM Lai CI Li CC Chen PC Chang WY Lin YD Lee T Lin TC Li, BMC Public Health 2007 7 1 739 743
26. In addition to insulin resistance and obesity, hyperuricemia is strongly associated with metabolic syndrome using different definitions in Chinese populations: a population-based study (Taichung Community Health Study). WY Lin CS Liu TC Li T Lin Walter Chen CC Chen CI Li CC Lin, Ann Rheum Dis 2008 67 3 432 433 10.1136/ard.2007.073601 18292110
27. New bioimpedance analysis system: improved phenotyping with whole-body analysis. A Pietrobelli F Rubiano MP St Onge SB Heymsfield, Eur J Clin Nutr 2004 58 1479 1484 10.1038/sj.ejcn.1601993 15138459
28. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. JI Weitz J Byrne GP Clagett,, et al. Circulation 1996 94 3026 3049 8941154
29. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. DR Matthews JP Hosker AS Rudenski BA Naylor DF Treacher RC Turner, Diabetologia 1985 28 7 412 419 10.1007/BF00280883 3899825
30. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Foundation NK, Am J Kidney Dis 2002 39 2 Suppl 1 1 266 11904577
31. Prediction of coronary heart disease using risk factor categories. PW Wilson RB D'Agostino D Levy AM Belanger H Silbershatz WB Kannel, Circulation 1998 97 1837 1847 9603539
32. The metabolic syndrome: a historical context. Gaetano Crepaldi Stefania Maggi, Diabetes voice 2006 51 8 10
33. Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. SM Grundy JI Cleeman SR Daniels,, et al. Circulation 2005 112 2735 2752 10.1161/CIRCULATIONAHA.105.169404 16157765
34. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. JM Dekker C Girman T Rhodes G Nijpels CD Stehouwer LM Bouter RJ Heine, Circulation 2005 112 5 666 673 10.1161/CIRCULATIONAHA.104.516948 16061755
35. The measurement of observer agreement for categorical data. JR Landis GG Koch, Biometrics 1977 33 1 159 174 10.2307/2529310 843571
36. Analysis of agreement among definitions of metabolic syndrome in nondiabetic Turkish adults: a methodological study. AS Can TP Bersot, BMC Public Health 2007 7 353 10.1186/1471-2458-7-353 18088443
37. Concordance Between the 2005 International Diabetes Federation Definition for Diagnosing Metabolic Syndrome With the National Cholesterol Education Program Adult Treatment Panel III and the World Health Organization Definitions. F Guerrero-Romero M Rodriguez-Moran, Diabetes Care 2005 28 2588a 2589 10.2337/diacare.28.10.2588a
38. Prevalence and cardiovascular disease risk of the metabolic syndrome using National Cholesterol Education Program and International Diabetes Federation definitions in the Korean population. KM Choi SM Kim YE Kim DS Choi SH Baik J Lee, Metabolism 2007 56 552 558 10.1016/j.metabol.2006.12.003 17379016
39. Influence of body fat distribution on free fatty acid metabolism in obesity. MD Jensen MW Haymond RA Rizza PE Cryer JM Miles, J Clin Invest 1989 83 4 1168 1173 10.1172/JCI113997 2649512
40. The impact of central obesity as a prerequisite for the diagnosis of metabolic syndrome. CM Khoo CF Liew SK Chew ES Tai, Obesity (Silver Spring) 2007 15 262 269 10.1038/oby.2007.559 17228055
41. The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. C Lorenzo K Williams KJ Hunt SM Haffner, Diabetes Care 2007 30 8 13 10.2337/dc06-1414 17192325
42. Identification of subjects with insulin resistance and beta-cell dysfunction using alternative definitions of the metabolic syndrome. AJ Hanley LE Wagenknecht RB D'Agostino Jr B Zinman SM Haffner, Diabetes 2003 52 2740 2747 10.2337/diabetes.52.11.2740 14578292
43. Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations. G Assmann R Guerra G Fox P Cullen H Schulte D Willett SM Grundy, Am J Cardiol 2007 99 541 548 10.1016/j.amjcard.2006.08.045 17293200
44. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. ES Ford, Diabetes Care 2005 28 2745 2749 10.2337/diacare.28.11.2745 16249550
45. The metabolic syndrome in Australia: prevalence using four definitions. AJ Cameron DJ Magliano PZ Zimmet T Welborn JE Shaw, Diabetes Res Clin Pract 2007 77 471 478 10.1016/j.diabres.2007.02.002 17350710
46. Comparison of different definitions of the metabolic syndrome. A Sandhofer B Iglseder B Paulweber CF Ebenbichler JR Patsch, Eur J Clin Inves 2007 37 109 116 10.1111/j.1365-2362.2007.01751.x (Pubitemid 46066490)
47. Probable blind spot in the International Diabetes Federation definition of metabolic syndrome. HJ Chen WH Pan, Obesity (Silver Spring) 2007 15 1096 1100 10.1038/oby.2007.633 17495185
48. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study. G de Simone RB Devereux M Chinali LG Best ET Lee JM Galloway HE Resnick, Diabetes Care 2007 30 1851 1856 10.2337/dc06-2152 17440172
49. IDF and ATP-III definitions of metabolic syndrome in the prediction of all-cause mortality in type 2 diabetic patients. M Monami N Marchionni G Masotti E Mannucci, Diabetes Obes Metab 2007 9 350 353 10.1111/j.1463-1326.2006.00615.x 17391162
50. The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects - a population-based study comparing three different definitions. PM Nilsson G Engstrom B Hedblad, Diabet Med 2007 24 464 472 10.1111/j.1464-5491.2007.02142.x 17381496
51. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. M Matsuda RA DeFronzo, Diabetes Care 1999 22 1462 1470 10.2337/diacare.22.9.1462 10480510
52. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. E Bonora S Kiechl J Willeit F Oberhollenzer G Egger G Targher M Alberiche RC Bonadonna M Muggeo, Diabetes 1998 47 1643 1649 10.2337/diabetes.47.10.1643 9753305